Aerovate Therapeutics Inc expected to post a loss of 71 cents a share - Earnings Preview

Reuters · 03/25 11:07
Aerovate Therapeutics Inc <AVTE.OQ> expected to post a loss of 71 cents a share - Earnings Preview
  • Aerovate Therapeutics Inc AVTE.OQ AVTE.O is expected to show change in quarterly revenue when it reports results on March 27 (estimated) for the period ending December 31 2023


  • ​LSEG's mean analyst estimate for Aerovate Therapeutics Inc is for a loss of 71 cents per share.

  • The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 7 "strong buy" or "buy," "hold" and "sell" or "strong sell."

  • The mean earnings estimate of analysts was unchanged in the last three months. ​

  • Wall Street's median 12-month price target for Aerovate Therapeutics Inc is $35.50​, above​ its last closing price of $25.78. ​​​

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING

STARMINESMARTESTIMATE®

LSEG IBES ESTIMATE

ACTUAL

BEAT, MET, MISSED

SURPRISE %

Sep. 30 2023

-0.70

-0.69

-0.71

Missed

-2.7

Jun. 30 2023

-0.70

-0.70

-0.76

Missed

-9.2

Mar. 31 2023

-0.61

-0.60

-0.67

Missed

-11.7​

Dec. 31 2022

-0.71

-0.62

-0.61

Beat

1.3

​​Sep. 30 2022

-0.50

-0.50

-0.56

Missed

-12.4

Jun. 30 2022

-0.46

-0.45

-0.49

Missed

-7.8​

Mar. 31 2022

-0.34

-0.28

-0.45

Missed

-62.2

Dec. 31 2021

-0.26

-0.31

-0.35

Missed

-13.8

This summary was machine generated March 25 at 11:07 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)